-
1.发明申请INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开用于治疗神经病变性疾病的氨基酸衍生物和相关化合物公开(公告)号：US20160324828A1
公开(公告)日：2016-11-10
申请号：US15215750
申请日：2016-07-21
Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&D , reMYND
Inventor： Gerard Griffioen , Tom Van Dooren , Veronica Rojas de la Parra , Arnaud Marchand , Sara Allasia , Amuri Kilonda , Patrick Chaltin
IPC: A61K31/4045 , A61K31/4155 , A61K31/427 , A61K31/635 , A61K31/4192 , A61K31/4245 , A61K31/4178 , A61K31/497 , A61K31/422 , A61K31/4439
CPC classification number: A61K31/4045 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/497 , A61K31/635 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
Abstract translation: 本发明提供了新的化合物和用作药物的新化合物，更特别是用于预防或治疗神经变性疾病，更具体地，某些神经系统疾病，例如统称为tau蛋白病的病症，以及细胞毒性α-突触核蛋白淀粉样变性特征的病症 。 本发明还涉及所述新化合物在制备可用于治疗这种神经变性疾病的药物中的用途。 本发明还涉及包含所述新化合物的药物组合物和制备所述新化合物的方法。
-
2.发明授权Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases 有权吲哚酰胺衍生物和用于治疗神经变性疾病的相关化合物公开(公告)号：US09434722B2
公开(公告)日：2016-09-06
申请号：US14060563
申请日：2013-10-22
Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&D , reMYND
Inventor： Gerard Griffioen , Tom Van Dooren , Veronica Rojas De La Parra , Arnaud Marchand , Sara Allasia , Amuri Kilonda , Patrick Chaltin
IPC: C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
CPC classification number: A61K31/4045 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/497 , A61K31/635 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
Abstract translation: 本发明提供了新的化合物和用作药物的新化合物，更特别是用于预防或治疗神经变性疾病，更具体地，某些神经系统疾病，例如统称为tau蛋白病的病症，以及细胞毒性α-突触核蛋白淀粉样变性特征的病症 。 本发明还涉及所述新化合物在制备可用于治疗这种神经变性疾病的药物中的用途。 本发明还涉及包含所述新化合物的药物组合物和制备所述新化合物的方法。
-
3.发明申请INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES 有权用于治疗神经病变性疾病的氨基酸衍生物和相关化合物公开(公告)号：US20140066457A1
公开(公告)日：2014-03-06
申请号：US14060563
申请日：2013-10-22
Applicant: reMYND , Katholieke Universiteit Leuven, K.U.Leuven R&D
Inventor： Gerard Griffioen , Tom Van Dooren , Veronica Rojas De La Parra , Arnaud Marchand , Sara Allasia , Amuri Kilonda , Patrick Chaltin
IPC: C07D417/14 , C07D417/12 , C07D409/14 , C07D413/12 , C07D413/14
CPC classification number: A61K31/4045 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/497 , A61K31/635 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
Abstract translation: 本发明提供新的化合物和用作药物的新化合物，更特别是用于预防或治疗神经变性疾病，更具体地说是某些神经系统疾病，例如统称为tau蛋白病的病症，以及细胞毒性α-突触核蛋白淀粉样变性特征的病症 。 本发明还涉及所述新化合物在制备可用于治疗这种神经变性疾病的药物中的用途。 本发明还涉及包含所述新化合物的药物组合物和制备所述新化合物的方法。
-
公开(公告)号：US10117850B2
公开(公告)日：2018-11-06
申请号：US15215750
申请日：2016-07-21
Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&D , reMYND
Inventor： Gerard Griffioen , Tom Van Dooren , Veronica Rojas de la Parra , Arnaud Marchand , Sara Allasia , Amuri Kilonda , Patrick Chaltin
IPC: A61K31/4045 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/497 , A61K31/635 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
-
Patent Agency Ranking
5.发明申请公开(公告)号：US20190054068A1
公开(公告)日：2019-02-21
申请号：US16135593
申请日：2018-09-19
Applicant: Katholieke Universiteit Leuven, K.U. Leuven R&D , reMYND
Inventor： Gerard Griffioen , Tom Van Dooren , Veronica Rojas de la Parra , Arnaud Marchand , Sara Allasia , Amuri Kilonda , Patrick Chaltin
IPC: A61K31/4045 , C07D417/12 , C07D417/14 , C07D413/12 , C07D409/14 , C07D405/14 , C07D403/12 , A61K31/4245 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/635 , A61K31/427 , A61K31/4439 , A61K31/497 , C07D413/14
Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
-
6.发明申请公开(公告)号：US20230099111A1
公开(公告)日：2023-03-30
申请号：US18058109
申请日：2022-11-22
Applicant: reMYND N.V. , Katholieke Universiteit Leuven
Inventor： Johan Gerard Griffioen , Katrien Princen , Tom Francois L. Van Dooren , Arnaud Didier Marie Marchand , Amuri Kilonda , Sara Allasia , Patrick Chaltin
IPC: C07D413/12 , A61P25/28
Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
-
7.发明授权公开(公告)号：US11548881B2
公开(公告)日：2023-01-10
申请号：US16612096
申请日：2018-05-11
Applicant: reMYND N.V. , Katholieke Universiteit Leuven
Inventor： Johan Gerard Griffioen , Katrien Princen , Tom Francois L. Van Dooren , Arnaud Didier Marie Marchand , Amuri Kilonda , Sara Allasia , Patrick Chaltin
IPC: C07D413/12 , A61P25/28
Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
-
8.发明申请公开(公告)号：US20200095238A1
公开(公告)日：2020-03-26
申请号：US16612096
申请日：2018-05-11
Applicant: reMYND N.V. , Katholieke Universiteit Leuven
Inventor： Johan Gerard Griffioen , Katrien Princen , Tom Francois L. Van Dooren , Arnaud Didier Marie Marchand , Amuri Kilonda , Sara Allasia , Patrick Chaltin
IPC: C07D413/12 , A61P25/28
Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
-
9.发明授权公开(公告)号：US11939324B2
公开(公告)日：2024-03-26
申请号：US18058109
申请日：2022-11-22
Applicant: reMYND N.V. , Katholieke Universiteit Leuven
Inventor： Johan Gerard Griffioen , Katrien Princen , Tom Francois L. Van Dooren , Arnaud Didier Marie Marchand , Amuri Kilonda , Sara Allasia , Patrick Chaltin
IPC: C07D413/12 , A61P25/28
CPC classification number: C07D413/12 , A61P25/28
Abstract: The present invention relates to a compound of formula (I) or a tautomer thereof, wherein R1, R2, R3, R4 and R5, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of epilepsy and/or neurodegenerative diseases.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.203 seconds)
